Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

18.12.2017

Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

unTOUCHABLE ART, Russia’s first sociocultural trip, was held in Saint-Petersburg in December. BIOCAD, a biotechnology company, demonstrated how “immortal” HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs. The “IMMORTAL” installation devoted to the first ever cell line is part of a new science-art project that displays cancer research technologies.

More Category: Media release
BIOCAD launches the new manufacturing site in North Africa

30.11.2017

BIOCAD launches the new manufacturing site in North Africa

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided by the Russian manufacturer into the North African market. The manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer, approved in the first half of October 2017, will be based in Morocco. Besides Morocco, thеse biosimilars are planned to be marketed in Senegal, Gabon, and Côte d’Ivoire.

More Category: News
Russian biotechnology company BIOCAD prepares to enters the European market

30.10.2017

Russian biotechnology company BIOCAD prepares to enters the European market

The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. This are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.

More Category: Media release
BIOCAD’s rituximab biosimilar to receive MA soon in India

04.07.2017

BIOCAD’s rituximab biosimilar to receive MA soon in India

 On 20th of June 2017, the Central Drugs Standard Control Organization (CDSCO) has recommended Acellbia, the first rituximab biosimilar made in Russia, for approval in India.  In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD’s international expansion.

More Category: Media release
BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

06.06.2017

BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

In 2017, BIOCAD obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras under the trade name USMAL. First shipments will start in the beginning of the third quarter of 2017. BIOCAD will be able to supply as much rituximab as needed for Bolivian and Honduran patients. Considering competitive price of the Russian biosimilar, estimated drug availability will double.

More Category: News